FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136606951> ?p ?o ?g. }

• W3136606951 abstract "Background: The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the only zoonotic-origin CoV to reach the pandemic stage, to which neither an effective vaccine nor a specific therapy is available. The spike glycoprotein harbors the receptor-binding domain (RBD) that mediates the virus's entry to host cells. This study aimed to identify novel inhibitors that target the spike protein's RBD domain through computational screening of chemical and natural compounds. Method: The spike protein was modeled from the recently reported electron microscopy protein structure (PDB ID: 6VSB) and the previously described SARS-CoV protein structure (PDB ID: 6ACD and 6ACJ). Virtual lab bench CLC Drug Discovery was used to computationally screen for potential inhibitory effects of currently prescribed drugs (n = 22), natural antiviral drugs (n = 100), and natural compounds (n = 35032). Quantitative Structure-Activity Relationship (QSAR) studies were also performed to determine the leading binders known for their antiviral activity. Results: Among the drugs currently used to treat SARS-CoV2, hydroxychloroquine and favipiravir were identified as the best binders with an average of four H-bonds, with a binding affinity of − 36.66 kcal/mol and a minimum interaction energy of − 6.63 kcal/mol. In an evaluation of antiviral compounds, fosamprenavir and abacavir showed effective binding of five H-bonds, with an average binding affinity of − 18.75 kcal.mol − 1 and minimum interaction energy of − 3.57 kcal/mol. Furthermore, screening of 100 natural antiviral compounds predicted potential binding modes of glycyrrhizin, nepritin, punicalagin, epigallocatechin gallate, and theaflavin (average binding affinity of − 49.88 kcal/mol and minimum interaction energy of − 4.35 kcal/mol). Additionally, the study reports a list of 25 natural compounds that showed effective binding with an improved average binding affinity of − 51.46 kcal/mol. Conclusions: Using computational screening, we identified potential SARS-CoV-2 S glycoprotein inhibitors that bind to the RBD region. Using structure-based design and combination-based drug therapy, the identified molecules could be used to generate anti-SARS-CoV-2 drug candidates." @default.
• W3136606951 created "2021-03-29" @default.
• W3136606951 creator A5029565170 @default.
• W3136606951 creator A5062633191 @default.
• W3136606951 creator A5067880357 @default.
• W3136606951 creator A5080104005 @default.
• W3136606951 date "2021-04-29" @default.
• W3136606951 modified "2023-09-30" @default.
• W3136606951 title "Identification of potential natural inhibitors of the receptor-binding domain of the SARS-CoV-2 spike protein using a computational docking approach" @default.
• W3136606951 cites W1970658820 @default.
• W3136606951 cites W1999491936 @default.
• W3136606951 cites W2006718722 @default.
• W3136606951 cites W2015112775 @default.
• W3136606951 cites W2018408116 @default.
• W3136606951 cites W2026660579 @default.
• W3136606951 cites W2056271522 @default.
• W3136606951 cites W2079159737 @default.
• W3136606951 cites W2098924425 @default.
• W3136606951 cites W2105037592 @default.
• W3136606951 cites W2121293808 @default.
• W3136606951 cites W2131112384 @default.
• W3136606951 cites W2139915497 @default.
• W3136606951 cites W2255243349 @default.
• W3136606951 cites W2302013022 @default.
• W3136606951 cites W2556090342 @default.
• W3136606951 cites W2724799126 @default.
• W3136606951 cites W2739679816 @default.
• W3136606951 cites W2766193612 @default.
• W3136606951 cites W2886321229 @default.
• W3136606951 cites W2962765467 @default.
• W3136606951 cites W3001456238 @default.
• W3136606951 cites W3001897055 @default.
• W3136606951 cites W3007643904 @default.
• W3136606951 cites W3008142620 @default.
• W3136606951 cites W3009170734 @default.
• W3136606951 cites W3009577418 @default.
• W3136606951 cites W3010238729 @default.
• W3136606951 cites W3010673910 @default.
• W3136606951 cites W3011537081 @default.
• W3136606951 cites W3012083138 @default.
• W3136606951 cites W3012320055 @default.
• W3136606951 cites W3012862568 @default.
• W3136606951 cites W3013008917 @default.
• W3136606951 cites W3013348202 @default.
• W3136606951 cites W3013772162 @default.
• W3136606951 cites W3013800395 @default.
• W3136606951 cites W3014249633 @default.
• W3136606951 cites W3016922091 @default.
• W3136606951 cites W3021826725 @default.
• W3136606951 cites W3025790227 @default.
• W3136606951 cites W3029796571 @default.
• W3136606951 cites W3036970257 @default.
• W3136606951 cites W3047197438 @default.
• W3136606951 cites W3094396082 @default.
• W3136606951 cites W3096969432 @default.
• W3136606951 cites W3102609266 @default.
• W3136606951 cites W3175318380 @default.
• W3136606951 doi "https://doi.org/10.5339/qmj.2021.12" @default.
• W3136606951 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8474837" @default.
• W3136606951 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34604010" @default.
• W3136606951 hasPublicationYear "2021" @default.
• W3136606951 type Work @default.
• W3136606951 sameAs 3136606951 @default.
• W3136606951 citedByCount "9" @default.
• W3136606951 countsByYear W31366069512022 @default.
• W3136606951 countsByYear W31366069512023 @default.
• W3136606951 crossrefType "journal-article" @default.
• W3136606951 hasAuthorship W3136606951A5029565170 @default.
• W3136606951 hasAuthorship W3136606951A5062633191 @default.
• W3136606951 hasAuthorship W3136606951A5067880357 @default.
• W3136606951 hasAuthorship W3136606951A5080104005 @default.
• W3136606951 hasBestOaLocation W31366069511 @default.
• W3136606951 hasConcept C103697762 @default.
• W3136606951 hasConcept C159047783 @default.
• W3136606951 hasConcept C159110408 @default.
• W3136606951 hasConcept C164126121 @default.
• W3136606951 hasConcept C185592680 @default.
• W3136606951 hasConcept C41685203 @default.
• W3136606951 hasConcept C55493867 @default.
• W3136606951 hasConcept C65556437 @default.
• W3136606951 hasConcept C70721500 @default.
• W3136606951 hasConcept C71240020 @default.
• W3136606951 hasConcept C71924100 @default.
• W3136606951 hasConcept C74187038 @default.
• W3136606951 hasConcept C86803240 @default.
• W3136606951 hasConceptScore W3136606951C103697762 @default.
• W3136606951 hasConceptScore W3136606951C159047783 @default.
• W3136606951 hasConceptScore W3136606951C159110408 @default.
• W3136606951 hasConceptScore W3136606951C164126121 @default.
• W3136606951 hasConceptScore W3136606951C185592680 @default.
• W3136606951 hasConceptScore W3136606951C41685203 @default.
• W3136606951 hasConceptScore W3136606951C55493867 @default.
• W3136606951 hasConceptScore W3136606951C65556437 @default.
• W3136606951 hasConceptScore W3136606951C70721500 @default.
• W3136606951 hasConceptScore W3136606951C71240020 @default.
• W3136606951 hasConceptScore W3136606951C71924100 @default.
• W3136606951 hasConceptScore W3136606951C74187038 @default.
• W3136606951 hasConceptScore W3136606951C86803240 @default.
• W3136606951 hasIssue "1" @default.
• W3136606951 hasLocation W31366069511 @default.

• next